{"generic":"Dofetilide","drugs":["Dofetilide","Tikosyn"],"mono":[{"id":"925165-s-0","title":"Generic Names","mono":"Dofetilide"},{"id":"925165-s-1","title":"Dosing and Indications","sub":[{"id":"925165-s-1-4","title":"Adult Dosing","mono":"<ul><li>dofetilide is prescribed, and dispensed only by healthcare providers, hospitals, and pharmacies that are certified to have received appropriate dofetilide dosing and treatment initiation education; details available at 1-877-TIKOSYN or visit www.TIKOSYNREMS.com.<\/li><li>patients initiated, re-initiated, or undergoing dose escalation of dofetilide should be placed in a facility for a minimum of 3 days for proper monitoring; correct hypokalemia before initiating dofetilide therapy; patients should be anticoagulated prior to cardioversion<\/li><li>(switching from Class I or other Class III antiarrhythmic agents) withdraw for a minimum of 3 plasma half-lives before initiating dofetilide<\/li><li>(switching from amiodarone) initiate dofetilide only when amiodarone plasma levels are below 0.3 mcg\/mL or amiodarone has been discontinued for at least 3 months<\/li><li><b>Atrial fibrillation and flutter:<\/b> individualize dose according to CrCl and QTc<\/li><li><b>Atrial fibrillation and flutter:<\/b> (CrCl greater than 60 mL\/min and QTc 440 msec or less) initial dose 500 mcg ORALLY twice daily; determine QTc 2 to 3 hours after 1st dose; if QTc increases by more than 15% OR is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities), reduce dose to 250 mcg ORALLY twice daily; MAX dose 500 mcg ORALLY  twice daily<\/li><li><b>Atrial fibrillation and flutter - Chemical cardioversion:<\/b> individualize dose according to CrCl and QTc<\/li><li><b>Atrial fibrillation and flutter - Chemical cardioversion:<\/b> (CrCl greater than 60 mL\/min and QTc 440 msec or less) initial dose 500 mcg ORALLY twice daily; determine QTc 2 to 3 hours after 1st dose; if QTc increases by more than 15% OR is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities), reduce dose to 250 mcg ORALLY twice daily; MAX dose 500 mcg ORALLY  twice daily<\/li><\/ul>"},{"id":"925165-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in children less than 18 years of age "},{"id":"925165-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment (CrCl 40 to 60 mL\/min and QTc 440 msec or less):<\/b> initial dose 250 mcg ORALLY twice daily; determine QTc 2 to 3 hours after 1st dose; if QTc increases by more than 15% or is greater than 500 msec (550 msec in patients with ventricular conduction abnormalities), reduce  dose to 125 mcg ORALLY twice daily<\/li><li>renal impairment (CrCl 20 to less than 40 mL\/min and QTc 440 msec or less), initial dose 125 mcg ORALLY twice daily; determine QTc 2 to 3 hours after 1st dose; if QTc increases greater than 15% or greater than 500 msec (550 msec in patients with ventricular conduction abnormalities) reduce dose to 125 mcg ORALLY once daily<\/li><li>renal impairment (CrCl less than 20 mL.\/min); use contraindicated<\/li><li><b>hepatic impairment, mild-to-moderate:<\/b> no dosage adjustments are needed; effects have not been studied in patients with severe liver impairment<\/li><\/ul>"},{"id":"925165-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Atrial fibrillation and flutter<\/li><li>Atrial fibrillation and flutter - Chemical cardioversion<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Cardiac dysrhythmia; Prophylaxis - Congestive heart failure<\/li><li>Cardiac dysrhythmia; Prophylaxis - Impaired left ventricular function - Myocardial infarction with complication<\/li><li>Supraventricular arrhythmia; Treatment and Prophylaxis<\/li><li>Ventricular arrhythmia; Prophylaxis<\/li><li>Wolff-Parkinson-White syndrome<\/li><\/ul>"}]},{"id":"925165-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>To minimize the risk of induced arrhythmia, patients initiated or re-initiated on dofetilide should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous ECG monitoring, and cardiac resuscitation. Dofetilide is available only to hospitals and prescribers who have received appropriate dofetilide dosing and treatment initiation education.<br\/>"},{"id":"925165-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925165-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant use of cimetidine, dolutegravir, hydrochlorothiazide (alone or with triamterene), ketoconazole, megestrol, prochlorperazine, trimethoprim (alone or with sulfamethoxazole), or verapamil; increased risk of QT-interval prolongation<\/li><li>congenital or acquired long QT syndromes (QTc interval greater than 440 msec or 500 msec for patients with ventricular conduction abnormalities)<\/li><li>hypersensitivity to dofetilide<\/li><li>severe renal impairment (CrCl less than 20 mL\/min)<\/li><\/ul>"},{"id":"925165-s-3-10","title":"Precautions","mono":"<ul><li>ventricular arrhythmias associated with QT interval prolongation, primarily torsade de pointes, may occur; monitoring and dose adjustments recommended<\/li><li>concomitant use with drugs that prolong the QT interval and other antiarrhythmic agents (eg, phenothiazines, cisapride, bepridil, tricyclic antidepressants, certain oral macrolides, and certain fluoroquinolones; class I and III antiarrhythmics and amiodarone) is not recommended<\/li><li>concomitant use with CYP3A4 inhibitors (eg, macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, cannabinoids, diltiazem, grapefruit juice, nefazodone, norfloxacin, quinine, zafirlukast) and potassium-depleting diuretics<\/li><li>hepatic impairment, severe<\/li><li>hypokalemia; increased risk for torsade de pointes; monitoring recommended<\/li><li>hypomagnesemia; increased risk for torsade de pointes<\/li><li>renal impairment (CrCl of 60 mL\/min or less); dose adjustments recommended<\/li><\/ul>"},{"id":"925165-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"925165-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"925165-s-4","title":"Drug Interactions","sub":[{"id":"925165-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cimetidine (probable)<\/li><li>Cisapride (theoretical)<\/li><li>Dolutegravir (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Levomethadyl (theoretical)<\/li><li>Megestrol (probable)<\/li><li>Mesoridazine (established)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Sulfamethoxazole (probable)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Trimethoprim (probable)<\/li><li>Verapamil (probable)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"925165-s-4-14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Amiloride (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amisulpride (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aprindine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (probable)<\/li><li>Artemether (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Azosemide (probable)<\/li><li>Bedaquiline (theoretical)<\/li><li>Bemetizide (probable)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bretylium (theoretical)<\/li><li>Bumetanide (probable)<\/li><li>Buserelin (theoretical)<\/li><li>Buthiazide (probable)<\/li><li>Chloral Hydrate (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Chlorthalidone (probable)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clopamide (probable)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Cyclothiazide (probable)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Diazoxide (probable)<\/li><li>Dibenzepin (theoretical)<\/li><li>Digoxin (probable)<\/li><li>Dirithromycin (probable)<\/li><li>Disopyramide (probable)<\/li><li>Dolasetron (established)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Enflurane (theoretical)<\/li><li>Erythromycin (probable)<\/li><li>Escitalopram (theoretical)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Etozolin (probable)<\/li><li>Fenquizone (probable)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Furosemide (probable)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (probable)<\/li><li>Haloperidol (theoretical)<\/li><li>Halothane (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Indapamide (probable)<\/li><li>Isoflurane (theoretical)<\/li><li>Isradipine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Josamycin (probable)<\/li><li>Lamotrigine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lidoflazine (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lorcainide (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Methyclothiazide (probable)<\/li><li>Metolazone (probable)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Moricizine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Prilocaine (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinethazone (probable)<\/li><li>Quinidine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Roxithromycin (probable)<\/li><li>Salmeterol (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Spiramycin (theoretical)<\/li><li>Sultopride (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tizanidine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Torsemide (probable)<\/li><li>Trazodone (theoretical)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Troleandomycin (probable)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vasopressin (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Xipamide (probable)<\/li><li>Zolmitriptan (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"}]},{"id":"925165-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (10%)<\/li><li><b>Neurologic:<\/b>Dizziness (8%), Headache (11%)<\/li><\/ul><b>Serious<\/b><br\/><b>Cardiovascular:<\/b>Heart block (up to 1.2%), Prolonged QT interval, Torsades de pointes (0.8%), Ventricular arrhythmia (up to 14.5%), Ventricular fibrillation (up to 4.8%), Ventricular tachycardia (up to 12.4%)<br\/>"},{"id":"925165-s-6","title":"Drug Name Info","sub":{"0":{"id":"925165-s-6-17","title":"US Trade Names","mono":"Tikosyn<br\/>"},"2":{"id":"925165-s-6-19","title":"Class","mono":"<ul><li>Antiarrhythmic, Group III<\/li><li>Methanesulfonanilide<\/li><\/ul>"},"3":{"id":"925165-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"925165-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},{"id":"925165-s-7","title":"Mechanism Of Action","mono":"Systemic: Dofetilide prolongs cardiac action potential duration and effective refractory period without affecting conduction velocity.Dofetilide selectively blocks the cardiac delayed rectifier potassium current (IK), specifically, the rapid component of the current (Ikr). At clinically relevant concentrations, dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors. In the Vaughan Williams classification of antiarrhythmics, dofetilide is considered to be a pure Class III agent. <br\/>"},{"id":"925165-s-8","title":"Pharmacokinetics","sub":[{"id":"925165-s-8-23","title":"Absorption","mono":"Systemic: Bioavailability: &gt;90%; food effects none <br\/>"},{"id":"925165-s-8-24","title":"Distribution","mono":"Systemic: Vd: 3 L\/kg <br\/>"},{"id":"925165-s-8-25","title":"Metabolism","mono":"Systemic: Hepatic: via CYP3A4 pathway <br\/>"},{"id":"925165-s-8-26","title":"Excretion","mono":"Systemic: Renal: 80% (80% unchanged; 20% metabolites)<br\/>"},{"id":"925165-s-8-27","title":"Elimination Half Life","mono":"Systemic: 10 h <br\/>"}]},{"id":"925165-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/>administer with or without food <br\/>"},{"id":"925165-s-10","title":"Monitoring","mono":"<ul><li>conversion to, and maintenance of normal sinus rhythm is evidence of efficacy<\/li><li>serum creatinine; prior to initiating therapy and continue to calculate clearance for a minimum of 3 days while the patient is in a facility during initiation or reinitiation of dofetilide therapy<\/li><li>renal function; every 3 months or as medically indicated<\/li><li>potassium levels; prior to initiating and during therapy<\/li><li>ECG; determine the QTc interval prior to initiating dofetilide therapy and at 2 to 3 hours following the first dose, and continuously for a minimum of 3 days or for a minimum of 12 hours following electrical or pharmacological conversion to normal sinus rhythm, whichever is greater while the patient is in a facility during initiation or reinitiation of dofetilide therapy; QTc should be re-evaluated every 3 months or as medically indicated; if QTc exceed 500 msec (550 msec in patients with ventricular conduction abnormalities) carefully monitor the patient following discontinuation of dofetilide therapy until the QTc returns to baseline levels<\/li><\/ul>"},{"id":"925165-s-11","title":"How Supplied","mono":"<b>Tikosyn<\/b><br\/>Oral Capsule: 0.125 MG, 0.25 MG, 0.5 MG<br\/>"},{"id":"925165-s-12","title":"Toxicology","sub":[{"id":"925165-s-12-31","title":"Clinical Effects","mono":"<b>DOFETILIDE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Overdose experience is limited.  Effects reported include QT prolongation, torsade de pointes and complete heart block. ADVERSE EFFECTS: Dofetilide may induce or worsen ventricular dysrhythmias, producing life threatening polymorphic ventricular tachycardia. Other adverse effects that may occur following dofetilide administration include chest pain, nausea, abdominal pain, flatulence, diarrhea, headache, dizziness, and fatigue.<br\/>"},{"id":"925165-s-12-32","title":"Treatment","mono":"<b>DOFETILIDE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: Activated charcoal if patient is alert or airway is protected. Gastric lavage for recent, large ingestion.<\/li><li>Ventricular arrhythmia: Cardioversion if unstable. Administer lidocaine. Correct underlying electrolyte abnormalities. Avoid Class 1A (disopyramide, procainamide, quinidine), Class 1C (encainide, flecainide, lorcainide), sotalol and amiodarone because they may further prolong the QT interval and predispose to torsades de pointes.<\/li><li>Torsades de pointes: Hemodynamically unstable patients require electrical cardioversion.  Emergent treatment with magnesium or atrial overdrive pacing is indicated.  Detect and correct underlying electrolyte abnormalities.<\/li><li>Enhanced elimination procedure: Hemodialysis is unlikely to remove significant amounts of dofetilide due to its large volume of distribution.<\/li><li>Monitoring of patient: Continuous cardiac monitoring and serial ECGs are recommended.  Monitor vital signs. Monitoring should be continued until the QT interval normalizes or returns to baseline. Monitor serum potassium and magnesium.<\/li><\/ul>"},{"id":"925165-s-12-33","title":"Range of Toxicity","mono":"<b>DOFETILIDE AND RELATED AGENTS<\/b><br\/>TOXICITY: Toxic manifestations are usually an extension of the pharmacological activity (torsade de pointes).  Oral dofetilide doses of 500 mcg twice daily have been associated with an increased risk of developing torsades de pointes; sudden death has been reported in one patient. A patient received two 500 mcg dofetilide doses one hour apart and  developed ventricular fibrillation and cardiac arrest 2 hours after the second dose. THERAPEUTIC: ADULT: Dofetilide dosing is based on creatinine clearance - (CrCl &gt; 60 mL\/min) 500 mcg twice daily; (CrCl 40 - 60 mL\/min) 250 mcg twice daily; (CrCl 20 - &lt;40 mL\/min) 125 mcg twice daily; (CrCl &lt; 20 mL\/min) contraindicated. CHILD: Safety and efficacy have not been established in children.<br\/>"}]},{"id":"925165-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause nausea, dizziness, headache, or dyspnea.<\/li><li>Instruct patient to report signs\/symptoms of angina or arrhythmias.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><li>Patient should not eat grapefruit or drink grapefruit juice while taking this drug.<\/li><\/ul>"}]}